Poly(ADP-ribose)polymerase inhibitors-associated myeloid neoplasms: a retrospective study from the French Network of Pharmacovigilance centres

Pierre-Marie Morice; Alexis Genthon; Thomas Boyer; Kevin Bihan; Julien Mahé; Anthony Sourisseau; Hélène Peyrouzet; Ghada Miremont; Marion Lepelley; Laetitia Stefani; Louise Gaboriau; Fanny Rocher; Danièle Aquaronne; Christine Le Beller; Marion Allouchery; Brahim Azzouz; Nathalie Massy; Martine Alt-Tebacher; Célestine Simand; Raoul Herbrecht; Basile Chrétien; Charles Dolladille; Sylvain Chantepie; Joachim Alexandre

doi:10.1111/bjh.17863

Poly(ADP-ribose)polymerase inhibitors-associated myeloid neoplasms: a retrospective study from the French Network of Pharmacovigilance centres

Br J Haematol. 2022 Feb;196(3):787-793. doi: 10.1111/bjh.17863. Epub 2021 Oct 5.

Authors

Pierre-Marie Morice^{1

2}, Alexis Genthon³, Thomas Boyer⁴, Kevin Bihan⁵, Julien Mahé⁶, Anthony Sourisseau⁷, Hélène Peyrouzet⁸, Ghada Miremont^{8

9}, Marion Lepelley¹⁰, Laetitia Stefani¹¹, Louise Gaboriau¹², Fanny Rocher¹³, Danièle Aquaronne¹⁴, Christine Le Beller¹⁵, Marion Allouchery¹⁶, Brahim Azzouz^{17

18}, Nathalie Massy¹⁹, Martine Alt-Tebacher²⁰, Célestine Simand²¹, Raoul Herbrecht²¹, Basile Chrétien²², Charles Dolladille^{1

22}, Sylvain Chantepie², Joachim Alexandre^{1

22}

Affiliations

¹ UNICAEN, INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment), Normandie Univ, Caen, France.
² Department of Clinical Hematology, Caen University Hospital, Caen, France.
³ Department of Clinical Haematology, Saint Antoine Hospital, Sorbonne University, INSERM UMR-S 938, Paris, France.
⁴ Laboratory of Hematology, Amiens University Hospital, Amiens, France.
⁵ Regional Pharmacovigilance Center, Department of Pharmacology, Pitié-Salpêtrière University Hospital, Paris, France.
⁶ Regional Pharmacovigilance Center, Department of Clinical Pharmacology, CHU of Nantes, Nantes, France.
⁷ Departement of Pharmacy, Hotel Dieu University Hospital, Nantes, France.
⁸ Public Health Unit, Department of Medical Pharmacology, Regional Pharmacovigilance Center, Bordeaux University Hospital, Bordeaux, France.
⁹ INSERM, BPH, U1219, Team Pharmacoepidemiology, Univ. Bordeaux, Bordeaux, France.
¹⁰ Regional Pharmacovigilance Center, Department of Public Health, Grenoble-Alpes University Hospital, Grenobles, France.
¹¹ Department of Medical Oncology, Annecy-Genevois Hospital, Epagny Metz-Tessy, France.
¹² Regional Pharmacovigilance Center, Department of Pharmacology, Lille University Hospital, Lille, France.
¹³ Regional Pharmacovigilance Center, Department of Pharmacology, Cimiez University Hospital, Nice, France.
¹⁴ Laboratory of Hematology, Pasteur University Hospital, Nice, France.
¹⁵ Innovative Therapies in Hemostasis, INSERM, Pharmacovigilance Department, Assistance Publique Hôpitaux de Paris-Centre (APHP-CUP), Paris University, Paris, France.
¹⁶ Regional Pharmacovigilance Center, Department of Clinical Pharmacology, Poitiers University, Poitiers University Hospital, Poitiers, France.
¹⁷ Regional Centre of Pharmacovigilance and Pharmacoepidemiology, Reims University Hospital, Reims, France.
¹⁸ EA 3797, Faculty of Medicine, University of Reims Champagne-Ardenne, Reims, France.
¹⁹ Regional Pharmacovigilance Center, Department of Pharmacology, Rouen University Hospital, Rouen, France.
²⁰ Regional Pharmacovigilance Center, Cardiology Department, Strasbourg University Hospital, Strasbourg, France.
²¹ Department of Hematology, Institute for Cancer Strasbourg-Europe (ICANS), Strasbourg University, Strasbourg, France.
²² Regional Pharmacovigilance Center, Department of Pharmacology, Caen University Hospital, Caen, France.

PMID: 34611896
DOI: 10.1111/bjh.17863

No abstract available

Publication types

Letter
Multicenter Study

MeSH terms

Cross-Sectional Studies
Female
France / epidemiology
Humans
Male
Myeloproliferative Disorders / diagnosis
Myeloproliferative Disorders / epidemiology
Myeloproliferative Disorders / etiology*
Neoplasms, Second Primary / diagnosis
Neoplasms, Second Primary / epidemiology
Neoplasms, Second Primary / etiology*
Pharmacovigilance
Poly(ADP-ribose) Polymerase Inhibitors / adverse effects*
Poly(ADP-ribose) Polymerase Inhibitors / therapeutic use
Retrospective Studies

Substances

Poly(ADP-ribose) Polymerase Inhibitors